Urological Cancer 2021
Cancer of the urological sphere is a disease continuously increasing in numbers in the statistics of tumor malignancies in Western countries. Although this fact is mainly due to the contemporary increase of life expectancy of the people in these geographic areas, many other factors do contribute as...
Saved in:
TeilnehmendeR: | |
---|---|
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 electronic resource (328 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993544476204498 |
---|---|
ctrlnum |
(CKB)5720000000008448 (oapen)https://directory.doabooks.org/handle/20.500.12854/84579 (EXLCZ)995720000000008448 |
collection |
bib_alma |
record_format |
marc |
spelling |
Urological Cancer 2021 MDPI - Multidisciplinary Digital Publishing Institute 2022 1 electronic resource (328 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Cancer of the urological sphere is a disease continuously increasing in numbers in the statistics of tumor malignancies in Western countries. Although this fact is mainly due to the contemporary increase of life expectancy of the people in these geographic areas, many other factors do contribute as well to this growth. Urological cancer is a complex and varied disease of different organs and mainly affects the male population. In fact, kidney, prostate, and bladder cancer are regularly included in the top-ten list of the most frequent neoplasms in males in most statistics. The female population, however, has also increasingly found itself affected by renal and bladder cancer in the last decade. Considering these altogether, urological cancer is a problem of major concern in developed societies. This Topic Issue of Cancers intends to shed some light into the complexity of this field and will consider all useful and appropriate contributions that scientists and clinicians may provide to improve urological cancer knowledge for patients’ benefit. The precise identification of the molecular routes involved, the diagnostic pathological criteria in the grey zones, the dilemma of T1G3 management, and the possible treatment options between superficial, nonmuscle-invasive and muscle-invasive diseases will be particularly welcomed in this Issue. English Research. Chemistry. bladder cancer radiotherapy radiosensitisation molecular subtypes preclinical studies bladder cancer cell lines latent cancer prostate cancer autopsy prognostic index prediction model mortality screening trial renal cell carcinoma PD-1 PD-L1 biomarkers immune checkpoint inhibitors prostatic neoplasms positron-emission tomography decision making tumor thrombus metastasectomy postoperative complications oncological outcomes radical cystectomy AHNAK2 prognosis dog comparative oncology inflammation prostatic atrophy preneoplastic lesion biomarker urine machine learning TRIPOD liquid biopsy glutaminase immunohistochemistry in situ methods prostate PSMA-RLT 177Lu-PSMA PSA mCRPC urinary bladder neoplasms Bacillus Calmette-Guérin (BCG) immunotherapy divergent differentiation variant morphology survival stereotactic body radiotherapy frail patients cancer metastasis genomic analysis microenvironment tumor ecology game theory fluorescence confocal microscopy prostate biopsy ablation margins focal therapy sphingosine 1-phosphate receptor 1 bladder carcinoma cell migration epithelial-mesenchymal transition FTY-720 OIP5 papillary renal cell carcinoma PLK1 tumorigenesis therapy image-guided magnetic resonance imaging ultrasonography biopsy abiraterone enzalutamide docetaxel novel hormonal therapies comparative effectiveness real-world treatment pattern metastatic prostate cancer epiplakin diagnosis advanced urothelial carcinoma immune checkpoint inhibitor prognostic tumour mutational board genomic signatures ctDNA inflammatory indices urothelial carcinoma frailty prognostic factor psoas muscle Hounsfield units 3-0365-3048-7 3-0365-3049-5 Manini, Claudia. editor. López, José I., editor. |
language |
English |
format |
eBook |
author2 |
Manini, Claudia. López, José I., |
author_facet |
Manini, Claudia. López, José I., |
author2_variant |
c m cm j i l ji jil |
author2_role |
TeilnehmendeR TeilnehmendeR |
title |
Urological Cancer 2021 |
spellingShingle |
Urological Cancer 2021 |
title_full |
Urological Cancer 2021 |
title_fullStr |
Urological Cancer 2021 |
title_full_unstemmed |
Urological Cancer 2021 |
title_auth |
Urological Cancer 2021 |
title_new |
Urological Cancer 2021 |
title_sort |
urological cancer 2021 |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2022 |
physical |
1 electronic resource (328 pages) |
isbn |
3-0365-3048-7 3-0365-3049-5 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT maniniclaudia urologicalcancer2021 AT lopezjosei urologicalcancer2021 |
status_str |
n |
ids_txt_mv |
(CKB)5720000000008448 (oapen)https://directory.doabooks.org/handle/20.500.12854/84579 (EXLCZ)995720000000008448 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Urological Cancer 2021 |
author2_original_writing_str_mv |
noLinkedField noLinkedField |
_version_ |
1796652272587898880 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05477nam-a2201489z--4500</leader><controlfield tag="001">993544476204498</controlfield><controlfield tag="005">20231220174817.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202206s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5720000000008448</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/84579</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995720000000008448</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Urological Cancer 2021</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (328 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cancer of the urological sphere is a disease continuously increasing in numbers in the statistics of tumor malignancies in Western countries. Although this fact is mainly due to the contemporary increase of life expectancy of the people in these geographic areas, many other factors do contribute as well to this growth. Urological cancer is a complex and varied disease of different organs and mainly affects the male population. In fact, kidney, prostate, and bladder cancer are regularly included in the top-ten list of the most frequent neoplasms in males in most statistics. The female population, however, has also increasingly found itself affected by renal and bladder cancer in the last decade. Considering these altogether, urological cancer is a problem of major concern in developed societies. This Topic Issue of Cancers intends to shed some light into the complexity of this field and will consider all useful and appropriate contributions that scientists and clinicians may provide to improve urological cancer knowledge for patients’ benefit. The precise identification of the molecular routes involved, the diagnostic pathological criteria in the grey zones, the dilemma of T1G3 management, and the possible treatment options between superficial, nonmuscle-invasive and muscle-invasive diseases will be particularly welcomed in this Issue.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Research.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Chemistry.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bladder cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">radiotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">radiosensitisation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular subtypes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">preclinical studies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bladder cancer cell lines</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">latent cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostate cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">autopsy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognostic index</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prediction model</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mortality</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">screening trial</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">renal cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PD-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PD-L1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostatic neoplasms</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">positron-emission tomography</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">decision making</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor thrombus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastasectomy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">postoperative complications</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncological outcomes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">radical cystectomy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">AHNAK2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dog</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">comparative oncology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostatic atrophy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">preneoplastic lesion</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">machine learning</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TRIPOD</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">liquid biopsy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glutaminase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunohistochemistry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">in situ methods</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostate</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PSMA-RLT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">177Lu-PSMA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PSA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mCRPC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urinary bladder neoplasms</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Bacillus Calmette-Guérin (BCG)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">divergent differentiation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">variant morphology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">survival</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stereotactic body radiotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">frail patients</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genomic analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microenvironment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor ecology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">game theory</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fluorescence confocal microscopy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostate biopsy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ablation margins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">focal therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sphingosine 1-phosphate receptor 1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bladder carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cell migration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epithelial-mesenchymal transition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">FTY-720</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">OIP5</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">papillary renal cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PLK1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumorigenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">image-guided</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">magnetic resonance imaging</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ultrasonography</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biopsy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">abiraterone</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">enzalutamide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">docetaxel</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">novel hormonal therapies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">comparative effectiveness</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">real-world treatment pattern</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastatic prostate cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epiplakin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">diagnosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">advanced urothelial carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognostic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumour mutational board</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genomic signatures</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ctDNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammatory indices</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urothelial carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">frailty</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognostic factor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">psoas muscle</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Hounsfield units</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-3048-7</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-3049-5</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Manini, Claudia.</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">López, José I.,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-22 01:58:10 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-07-02 22:45:44 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337635440004498&Force_direct=true</subfield><subfield code="Z">5337635440004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337635440004498</subfield></datafield></record></collection> |